Using advanced imaging to diagnose and predict treatment outcomes for bladder cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial investigates the effectiveness of FAPI PET/MRI and FDG PET/MRI imaging techniques in diagnosing muscle-invasive bladder cancer (MIBC) and predicting the success of neoadjuvant chemotherapy. Patients suspected of having MIBC will undergo these imaging examinations, along with standard MRI, to gather clinical and pathological data. The study aims to compare the accuracy of these imaging methods against postoperative results to refine treatment plans for patients. Additionally, it assesses the efficacy of neoadjuvant therapy through follow-up imaging and clinical evaluations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Inclusion criteria for MIBC diagnostic studies

  1. Patients with suspected muscle-invasive bladder cancer;
  2. Completion of FAPI PET/MRI, FDG PET/MRI and MRI;
  3. Complete clinical laboratory and pathological data.
* Inclusion criteria for MIBC neoadjuvant therapy efficacy evaluation study

  1. Patients diagnosed with muscle invasive bladder cancer;
  2. Completion of FAPI PET/MRI, FDG PET/MRI, and MRI before neoadjuvant therapy;
  3. Complete clinical laboratory and pathological data.

Exclusion Criteria:

* Exclusion criteria for MIBC diagnostic study

  1. Combined with other malignant tumors;
  2. Not receiving surgical treatment;
  3. Receiving neoadjuvant therapy before surgery;
  4. Previous allergy to contrast components or similar components;
  5. Serious organ function abnormalities, such as heart, lung, liver, kidney function serious abnormalities;
  6. Incomplete clinicopathological data
* Exclusion criteria of MIBC neoadjuvant therapy efficacy evaluation study

  1. Combination of other malignant tumors;
  2. FAPI PET/MRI, FDG PET/MRI and MRI were not completed after neoadjuvant therapy;
  3. Prior hypersensitivity to contrast components or similar components;
  4. Serious organ function abnormalities, such as serious abnormalities of heart, lung, liver and kidney function;
  5. Incomplete clinicopathological data.

Where it's running

• first hospital affiliated of Fujian medical university
  Fuzhou, Fujian, China Recruiting

Study contacts

• Study coordinator: Ning Xu, Doctor
• Email: drxun@fjmu.edu.cn
• Phone: 13235907575

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Inactivated UPEC-FimON for Bladder Cancer After BCG or Intravesical Therapy Failure

  This phase 1 study tests whether intravesical doses of inactivated UPEC-FimON are safe and tolerable in adults with non-muscle invasive bladder cancer that progressed after BCG or intravesical therapy.

  Recruiting at 3 sites Phase 1 Hopec Pharma · Kfar Saba, Central District and 2 other locations · NCT07881666

• Alpha1H before bladder tumor surgery in low/intermediate risk non-muscle-invasive bladder cancer

  This trial tests whether putting Alpha1H directly into the bladder before standard surgery helps prevent cancer from coming back or getting worse in adults with low- to intermediate-risk non-muscle-invasive bladder cancer.

  Recruiting Phase 3 Hamlet Pharma AB · Prague · NCT07804056

• Understanding how high-risk non-muscle-invasive bladder cancer is diagnosed and cared for in Portugal

  This study looks at how patients with high-risk non-muscle-invasive bladder cancer have been diagnosed and treated in regular care in Portugal.

  Recruiting Janssen-Cilag Farmaceutica Ltda. · Lisbon · NCT07784387

• Benchmarking AI language models against tumor boards for oncology treatment decisions

  This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Boulogne-Billancourt and 4 other locations · NCT07739121

• Real-world look at high-risk non-muscle-invasive bladder cancer after BCG in Korea

  This study tests how people with high-risk non-muscle-invasive bladder cancer fare after BCG therapy in real-world clinical settings in Korea.

  Recruiting Janssen Korea, Ltd., Korea · Suwon · NCT07735793

• Enfortumab vedotin plus pembrolizumab versus chemoradiotherapy for muscle-invasive bladder cancer

  This trial tests whether combining enfortumab vedotin with pembrolizumab can help people with non-metastatic muscle-invasive bladder cancer keep their bladder and control the cancer better than standard concurrent chemoradiotherapy.

  Recruiting at 29 sites Phase 3 Astellas Pharma Inc · Little Rock, Arkansas and 28 other locations · NCT07566156

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.